Biopolym. Cell. 2014; 30(5):343-348.
http://dx.doi.org/10.7124/bc.0008B0
Reviews
Relevance of targeting RET/PTC junction oncogene and Wnt/β-catenin pathway in the treatment of papillary thyroid carcinoma: skill of 8-year work
1Massaad-Massade L.
  1. CNRS UMR 8203, Universit Paris-Sud 11, Institut Gustave Roussy
    114, rue Edouard Vaillant, Villejuif, France, 94805

Abstract

Papillary thyroid carcinoma (PTC) is the most common endocrine gland malignancy and occurs frequently due to the radiation exposure. PTC is characterized by the paracentric inversion in chromosome 10 leading to the fusion of RET with several genes present in thyroid named PTC. The RET/PTCs junction oncogenes are present in around 80 % of papillary thyroid carcinoma, the most frequent ones are RET/PTC1 and RET/PTC3. Interestingly, RET/PTCs are found only in the tumour cells and not in the surrounding normal tissues, therefore, they represent a good target for RNA interference strategies. We aimed, on the one hand, to inhibit dedifferentiation due to the RET/PTC junction oncogene by siRNA and, on the other hand, to investigate a role of Wnt/β-catenin pathway in the regulation of a tissue-specific transcription factor, the thyroid transcription factor-1 (TTF-1) essential for the differentiation of the thyroid. In this paper we summarised our main results obtained during eight years that pointed a new therapeutic strategy for papillary thyroid carcinoma.
Keywords: papillary thyroid carcinoma, RET/PTCs junction oncogenes, siRNA, tumour cells
Full text: (PDF, in English)

References

[1] Leclere J, Orgiazzi J, Rousset B, et al. La thyroide: des concepts a la pratique clinique. Amsterdam, Elsevier, 2001; 618 p.
[2] Bingle CD. Thyroid transcription factor-1. Int J Biochem Cell Biol. 1997;29(12):1471-3.
[3] Endo T, Kaneshige M, Nakazato M, Ohmori M, Harii N, Onaya T. Thyroid transcription factor-1 activates the promoter activity of rat thyroid Na+/I- symporter gene. Mol Endocrinol. 1997;11(11):1747-55.
[4] Lin JD. Thyroglobulin and human thyroid cancer. Clin Chim Acta. 2008;388(1-2):15-21.
[5] Marotta V, Guerra A, Sapio MR, Vitale M. RET/PTC rearrangement in benign and malignant thyroid diseases: a clinical standpoint. Eur J Endocrinol. 2011;165(4):499-507.
[6] Tallini G, Asa SL. RET oncogene activation in papillary thyroid carcinoma. Adv Anat Pathol. 2001;8(6):345-54.
[7] Santoro M, Melillo RM, Fusco A. RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. Eur J Endocrinol. 2006;155(5):645-53.
[8] Romei C, Elisei R. RET/PTC Translocations and Clinico-Pathological Features in Human Papillary Thyroid Carcinoma. Front Endocrinol (Lausanne). 2012;3:54.
[9] Santoro M, Dathan NA, Berlingieri MT, Bongarzone I, Paulin C, Grieco M, Pierotti MA, Vecchio G, Fusco A. Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Oncogene. 1994;9(2):509-16.
[10] Nikiforova MN, Stringer JR, Blough R, Medvedovic M, Fagin JA, Nikiforov YE. Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. Science. 2000;290(5489):138-41.
[11] Nikiforov YE. RET/PTC rearrangement in thyroid tumors. Endocr Pathol. 2002 Spring;13(1):3-16.
[12] Manxhuka-Kerliu S, Devolli-Disha E, Gerxhaliu A, Ahmetaj H, Baruti A, Loxha S, Thaqi H. Prognostic values of thyroid tumours. Bosn J Basic Med Sci. 2009;9(2):111-9.
[13] Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A. Rational siRNA design for RNA interference. Nat Biotechnol. 2004;22(3):326-30.
[14] Gilbert-Sirieix M, Ripoche H, Malvy C, Massaad-Massade L. Effects of silencing RET/PTC1 junction oncogene in human papillary thyroid carcinoma cells. Thyroid. 2010;20(10):1053-65.
[15] Ali HM, Urbinati G, Chapuis H, Desmaele D, Bertrand JR, Couvreur P, Massaad-Massade L. Effects of siRNA on RET/PTC3 junction oncogene in papillary thyroid carcinoma: from molecular and cellular studies to preclinical investigations. PLoS One. 2014;9(4):e95964.
[16] Raouane M, Desma?le D, Urbinati G, Massaad-Massade L, Couvreur P. Lipid conjugated oligonucleotides: a useful strategy for delivery. Bioconjug Chem. 2012;23(6):1091-104.
[17] Ali HM, Urbinati G, Raouane M, Massaad-Massade L. Significance and applications of nanoparticles in siRNA delivery for cancer therapy. Expert Rev Clin Pharmacol. 2012;5(4):403-12.
[18] Raouane M, Desmaele D, Gilbert-Sirieix M, Gueutin C, Zouhiri F, Bourgaux C, Lepeltier E, Gref R, Ben Salah R, Clayman G, Massaad-Massade L, Couvreur P. Synthesis, characterization, and in vivo delivery of siRNA-squalene nanoparticles targeting fusion oncogene in papillary thyroid carcinoma. J Med Chem. 2011;54(12):4067-76.
[19] Ali HM, Maksimenko A, Urbinati G, Chapuis H, Raouane M, Desma?le D, Yasuhiro H, Harashima H, Couvreur P, Massaad-Massade L. Effects of silencing the RET/PTC1 oncogene in papillary thyroid carcinoma by siRNA-squalene nanoparticles with and without fusogenic companion GALA-cholesterol. Thyroid. 2014;24(2):327-38.
[20] Guazzi S, Price M, De Felice M, Damante G, Mattei MG, Di Lauro R. Thyroid nuclear factor 1 (TTF-1) contains a homeodomain and displays a novel DNA binding specificity. EMBO J. 1990;9(11):3631-9.
[21] Fabbro D, Di Loreto C, Beltrami CA, Belfiore A, Di Lauro R, Damante G. Expression of thyroid-specific transcription factors TTF-1 and PAX-8 in human thyroid neoplasms. Cancer Res. 1994;54(17):4744-9.
[22] Fenton CL, Patel A, Burch HB, Tuttle RM, Francis GL. Nuclear localization of thyroid transcription factor-1 correlates with serum thyrotropin activity and may be increased in differentiated thyroid carcinomas with aggressive clinical course. Ann Clin Lab Sci. 2001;31(3):245-52.
[23] Gilbert-Sirieix M, Massaad-Massade L. [TTF-1: neither angel nor demon]. Med Sci (Paris). 2011;27(2):183-6.
[24] Lloyd RV, Buehler D, Khanafshar E. Papillary thyroid carcinoma variants. Head Neck Pathol. 2011;5(1):51-6.
[25] Missero C, Cobellis G, De Felice M, Di Lauro R. Molecular events involved in differentiation of thyroid follicular cells. Mol Cell Endocrinol. 1998;140(1-2):37-43.
[26] Morin PJ. beta-catenin signaling and cancer. Bioessays. 1999;21(12):1021-30.
[27] Zhang J, Gill AJ, Issacs JD, Atmore B, Johns A, Delbridge LW, Lai R, McMullen TP. The Wnt/?-catenin pathway drives increased cyclin D1 levels in lymph node metastasis in papillary thyroid cancer. Hum Pathol. 2012;43(7):1044-50.
[28] Abbosh PH, Nephew KP. Multiple signaling pathways converge on beta-catenin in thyroid cancer. Thyroid. 2005;15(6):551-61.
[29] Gilbert-Sirieix M, Makoukji J, Kimura S, Talbot M, Caillou B, Massaad C, Massaad-Massade L. Wnt/?-catenin signaling pathway is a direct enhancer of thyroid transcription factor-1 in human papillary thyroid carcinoma cells. PLoS One. 2011;6(7):e22280.